Indoco Remedies Receives Final ANDA Approval for Brivaracetam Oral Solution
approval-for-rivaracetam-oral-solution'>Indoco Remedies Receives Final ANDA Approval for Brivaracetam Oral Solution is drawing significant interest across the industry.
Indoco Remedies announced final ANDA approval from USFDA for Brivaracetam Oral Solution 10 mg/mL, a generic equivalent to UCB's Briviact. The antiepileptic drug treats partial-onset seizures in patients 1 month and older, will be manufactured at the company's Goa facility, and represents a significant milestone in strengthening Indoco's presence in regulated markets.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- HC lifts stay, clears path for ‘Kerala Story 2’ release
- Panel to monitor scheme implementation: Jharkhand finance minister
- Red Sox walk back on statement shading Fanatics for botched uniform design
- 2030 French Alps Olympics CEO Cyril Linette departs amid internal turmoil
Source: Original →